COPENHAGEN — At the European Society of Cataract and Refractive Surgeons meeting here, Matthias Elling, MD, discussed the results of a prospective clinical trial of PiXL, or photorefractive intrastromal cross-linking, conducted in Germany using an epi-off technique for the correction of myopia up to –3 D.
This review takes a look at the current modalities as well as new treatment techniques used to manage microbial keratitis. The British Journal of Ophthalmology
COPENHAGEN — A secondary analysis of data gathered in the IVAN trial looking at the question of whether anti-VEGFs cause macular atrophy yielded no definitive answer but did evoke more questions.“We’ve all seen patients in clinic who have had a good response in terms of fluid but have ended up with a reduction in visual acuity due to progression of macular atrophy,” Clare Bailey, MD, said at the Euretina meeting. The follow-on analysis of 596 eyes was undertaken to more precisely grade macular lesions with particular attention given to location (Read more...)
Jason Brinton, MD, shares his perspective on the recent FDA approval of the VisuMax femtosecond laser for the small incision lenticule extraction (SMILE) procedure.
(MedPage Today) — Health news and commentary from around the Web, gathered by the MedPage Today staff
The FDA approved the VisuMax femtosecond laser to surgically reduce or eliminate myopia in certain patients 22 years of age or older. The VisuMax femtosecond laser (Carl Zeiss Meditec) was approved for the small incision lenticule extraction (SMILE) procedure, which removes a small amount of eye tissue to permanently reshape the patient’s cornea, according to an FDA press release.